MCID: BLR007
MIFTS: 58

Biliary Tract Neoplasm

Categories: Cancer diseases, Gastrointestinal diseases, Liver diseases, Rare diseases

Aliases & Classifications for Biliary Tract Neoplasm

MalaCards integrated aliases for Biliary Tract Neoplasm:

Name: Biliary Tract Neoplasm 12 29 15 73
Biliary Tract Cancer 76 53 55 73
Carcinoma of Extrahepatic Bile Duct 12 73
Extrahepatic Bile Duct Carcinoma 12 15
Extrahepatic Bile Duct Neoplasm 12 73
Malignant Tumor of Extrahepatic Bile Duct 73
Neoplasm of Extrahepatic Bile Ducts 12
Tumor of the Extrahepatic Bile Duct 12
Bile Duct Extrahepatic Carcinoma 55
Extrahepatic Bile Duct Cancer 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0050625 DOID:4682
NCIt 50 C4441 C3860
SNOMED-CT 68 93790004
ICD10 33 C24.0

Summaries for Biliary Tract Neoplasm

Disease Ontology : 12 A hepatobiliary benign neoplasm located in the biliary tract.

MalaCards based summary : Biliary Tract Neoplasm, also known as biliary tract cancer, is related to gallbladder adenoma and bile duct adenoma. An important gene associated with Biliary Tract Neoplasm is MUC2 (Mucin 2, Oligomeric Mucus/Gel-Forming), and among its related pathways/superpathways are Metabolism of proteins and Human cytomegalovirus infection. The drugs Isoflurane and Sevoflurane have been mentioned in the context of this disorder. Affiliated tissues include liver, small intestine and lung, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 Cholangiocarcinoma, also known as bile duct cancer, is a form of cancer that is composed of mutated... more...

Related Diseases for Biliary Tract Neoplasm

Diseases related to Biliary Tract Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 294)
# Related Disease Score Top Affiliating Genes
1 gallbladder adenoma 32.0 CDKN2A HRAS
2 bile duct adenoma 31.5 CDKN2A KRT7 MUC1
3 biliary papillomatosis 30.5 CDX2 HRAS KRAS KRT7 MUC1 MUC2
4 gallbladder cancer 29.9 CDKN2A KRAS MUC1 MUC2 TP53
5 small cell carcinoma 29.9 CDKN2A KRT7 TP53
6 adenosquamous carcinoma 29.7 KRAS KRT7 MUC1 MUC4 TP53
7 cholecystitis 29.6 CDKN2A MUC1 MUC2 TP53
8 bladder cancer 29.6 CDKN2A HRAS KRAS MUC2 TP53
9 lynch syndrome 29.5 CDKN2A KRAS MUC2 TP53
10 adenocarcinoma 29.2 CDKN2A HRAS KRAS MUC1 MUC4 SMAD4
11 gastric cancer 29.0 CDKN2A CDX2 KRAS MUC2 SMAD4 TP53
12 cholangiocarcinoma 29.0 CDX2 KRAS KRT7 MUC1 MUC2 MUC4
13 intrahepatic cholangiocarcinoma 29.0 CDX2 KRAS KRT7 MUC1 MUC2 MUC4
14 hepatocellular carcinoma 28.9 CDKN2A HRAS KRAS KRT7 SMAD4 TP53
15 pancreatic cancer 28.6 CDKN2A CDX2 HRAS KRAS MUC1 MUC2
16 klatskin's tumor 11.4
17 extrahepatic bile duct small cell adenocarcinoma 11.4
18 extrahepatic bile duct adenocarcinoma 11.4
19 extrahepatic bile duct adenoma 11.4
20 adenocarcinoma of the gallbladder and extrahepatic biliary tract 10.5
21 bile duct cancer 10.4
22 neuroendocrine tumor 10.4
23 meconium ileus 10.3 MUC1 MUC2
24 cholangitis 10.2
25 sarcomatoid mesothelioma 10.2 CDKN2A MUC4
26 carcinoid syndrome 10.2
27 gastric cardia carcinoma 10.2 MUC1 SMAD4
28 limbal stem cell deficiency 10.2 MUC1 MUC4
29 squamous cell carcinoma of gallbladder and extrahepatic biliary tract 10.2
30 filamentary keratitis 10.2 MUC1 MUC4
31 endometrial mucinous adenocarcinoma 10.2 CDKN2A MUC1
32 pleomorphic liposarcoma 10.2 CDKN2A MUC1
33 meningeal melanocytoma 10.2 CDKN2A MUC1
34 cholangiolocellular carcinoma 10.2 CDKN2A MUC1
35 ischemic fasciitis 10.2 CDKN2A MUC1
36 plasmablastic lymphoma 10.2 CDKN2A MUC1
37 polyposis, skin pigmentation, alopecia, and fingernail changes 10.2 CDX2 MUC2
38 microinvasive gastric cancer 10.2 CDX2 MUC2
39 suppressor of tumorigenicity 3 10.2 CDKN2A TP53
40 tongue disease 10.2 CDKN2A TP53
41 superior mesenteric artery syndrome 10.2 CDX2 MUC2
42 anogenital venereal wart 10.2 CDKN2A TP53
43 megaesophagus 10.2 CDKN2A TP53
44 penile disease 10.2 CDKN2A TP53
45 vulva squamous cell carcinoma 10.2 CDKN2A TP53
46 optic nerve neoplasm 10.2 CDKN2A TP53
47 scrotal carcinoma 10.2 CDKN2A TP53
48 verrucous carcinoma 10.2 CDKN2A TP53
49 keratinizing squamous cell carcinoma 10.2 CDKN2A TP53
50 anal squamous cell carcinoma 10.2 CDKN2A TP53

Comorbidity relations with Biliary Tract Neoplasm via Phenotypic Disease Network (PDN):


Acute Pancreatitis Cholangitis
Cholestasis Deficiency Anemia
Intrahepatic Gall Duct Cancer Pancreatic Cancer
Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Biliary Tract Neoplasm:



Diseases related to Biliary Tract Neoplasm

Symptoms & Phenotypes for Biliary Tract Neoplasm

GenomeRNAi Phenotypes related to Biliary Tract Neoplasm according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.47 HRAS KRAS MUC1
2 Decreased viability GR00106-A-0 9.47 KRAS
3 Decreased viability GR00221-A-1 9.47 HRAS KRAS
4 Decreased viability GR00221-A-2 9.47 HRAS KRAS
5 Decreased viability GR00221-A-3 9.47 HRAS
6 Decreased viability GR00301-A 9.47 KRAS
7 Decreased viability GR00381-A-1 9.47 KRAS
8 Decreased viability GR00402-S-2 9.47 HRAS KRAS MUC1

MGI Mouse Phenotypes related to Biliary Tract Neoplasm:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.95 CDKN2A CDX2 HRAS KRAS MUC2 SMAD4
2 digestive/alimentary MP:0005381 9.91 CDKN2A CDX2 HRAS KRAS MUC2 SMAD4
3 endocrine/exocrine gland MP:0005379 9.87 CDKN2A CDX2 HRAS KRAS MUC2 SMAD4
4 homeostasis/metabolism MP:0005376 9.86 CDKN2A CDX2 HRAS KRAS KRT7 MUC2
5 neoplasm MP:0002006 9.7 CDKN2A CDX2 HRAS KRAS MUC2 SMAD4
6 renal/urinary system MP:0005367 9.35 HRAS KRAS KRT7 SMAD4 TP53
7 skeleton MP:0005390 9.1 CDKN2A CDX2 HRAS KRAS SMAD4 TP53

Drugs & Therapeutics for Biliary Tract Neoplasm

Drugs for Biliary Tract Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 217)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Isoflurane Approved, Vet_approved Phase 4,Not Applicable 26675-46-7 3763
2
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
3
Desflurane Approved Phase 4,Not Applicable 57041-67-5 42113
4
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
5
Pancrelipase Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 53608-75-6
6 arginine Phase 4
7 Omega 3 Fatty Acid Phase 4
8 Anesthetics, Inhalation Phase 4,Not Applicable
9 Anesthetics, General Phase 4,Not Applicable
10 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Central Nervous System Depressants Phase 4,Not Applicable
12 Anesthetics Phase 4,Not Applicable
13 Platelet Aggregation Inhibitors Phase 4
14 Analgesics Phase 4,Phase 1,Not Applicable
15 Anti-Inflammatory Agents, Non-Steroidal Phase 4
16 Cyclooxygenase Inhibitors Phase 4
17 Cyclooxygenase 2 Inhibitors Phase 4
18 Anti-Inflammatory Agents Phase 4
19 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 pancreatin Phase 4,Phase 2,Phase 1,Not Applicable
21 Gastrointestinal Agents Phase 4,Phase 2,Not Applicable
22 Antirheumatic Agents Phase 4
23 Analgesics, Non-Narcotic Phase 4,Phase 1
24
Gemcitabine Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 95058-81-4 60750
25
Cisplatin Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
26
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1 61825-94-3 43805 6857599 5310940 9887054
27
leucovorin Approved Phase 3,Phase 2,Phase 1 58-05-9 6006 143
28
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
29
Levoleucovorin Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 68538-85-2
30
Irinotecan Approved, Investigational Phase 2, Phase 3,Phase 1 100286-90-6, 97682-44-5 60838
31
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
32
Epirubicin Approved Phase 3,Phase 1,Phase 2 56420-45-2 41867
33
Somatostatin Approved, Investigational Phase 3,Not Applicable 51110-01-1, 38916-34-6 53481605
34
Trioxsalen Approved Phase 3,Phase 2 3902-71-4 5585
35
Melphalan Approved Phase 2, Phase 3 148-82-3 4053 460612
36
Tegafur Approved, Investigational Phase 3,Phase 2,Phase 1 17902-23-7 5386
37
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 3,Phase 1,Phase 2 7487-88-9 24083
38
Citalopram Approved Phase 3 59729-33-8 2771
39
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1 59-30-3 6037
40
Cediranib Investigational Phase 2, Phase 3 288383-20-0 9933475
41 Antimetabolites Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
42 Immunosuppressive Agents Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
43 Immunologic Factors Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
44 Antiviral Agents Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
45 Anti-Infective Agents Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
46 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
47 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
48 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable
49 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
50 Photosensitizing Agents Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 351)
# Name Status NCT ID Phase Drugs
1 Effects of Preoperative Immunonutrition in Patients Undergoing Hepatectomy Unknown status NCT01256047 Phase 4
2 Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery Unknown status NCT02174575 Phase 4 Sevoflurane;Desflurane
3 Additional Effects of Perioperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy Unknown status NCT01969110 Phase 4
4 Cyclooxygenase-2 Inhibitor for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer Unknown status NCT01111591 Phase 4 Cox2 inhibitor (Celecoxib)
5 Radiofrequency Ablation for Malignant Biliary Obstruction Completed NCT01758341 Phase 4
6 Covered vs. Uncovered SEMS for Occluded Biliary Metal Stents Completed NCT01315522 Phase 4
7 RCT Steel (Wallstent®) vs Nitinol (Wallflex®) Bile Duct Stent for Palliation of Malignant Obstruction Completed NCT00980889 Phase 4
8 Effects of Preoperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy Completed NCT01256034 Phase 4
9 Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi Completed NCT01041612 Phase 4
10 Biliary Metal Stent Study: Metal Stents for Management of Distal Malignant Biliary Obstruction Completed NCT00280709 Phase 4
11 The Effect of Individualized Precision Therapy Programs in Patients With BTC Not yet recruiting NCT02943031 Phase 4
12 X-MAS Biliary Study With Covered Biliary Stent Unknown status NCT01899976 Phase 3
13 Early Enteral Feeding After Pylorus Preserving Pancreatoduodenectomy Unknown status NCT00809081 Phase 3
14 Cediranib Versus Placebo Plus Cisplatin/Gemcitabine Chemotherapy for Patients With Advanced Biliary Tract Cancers Completed NCT00939848 Phase 2, Phase 3 gemcitabine;cisplatin;Placebo;cisplatin;cediranib;gemcitabine
15 Nonstented Stump-closed vs Duct-to-Mucosa Pancreaticojejunostomy After Pancreaticoduodenectomy Completed NCT01731821 Phase 3
16 Early Palliative Care on Quality of Life of Advanced Cancer Patients Completed NCT02988635 Phase 3
17 Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by Surgery Completed NCT01313377 Phase 3 gemcitabine hydrochloride;oxaliplatin
18 Capecitabine or Observation After Surgery in Treating Patients With Biliary Tract Cancer Completed NCT00363584 Phase 3 capecitabine
19 New Chemotherapy Regimen in the Treatment of Advanced Gallbladder Carcinoma Completed NCT01053390 Phase 3 Somatostatin;epirubicin, cisplatin, LV(Leucovorin)、 5-FU(5-Fluorouracil)
20 Palliative Biliary Stenting on the Quality of Life of Patients With Unresectable Carcinoma Gallbladder With Hiliar Block. Completed NCT00391183 Phase 2, Phase 3
21 Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms Completed NCT01640522 Phase 3
22 Biliary Stenting With or Without Photodynamic Therapy in Treating Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors That Cannot Be Removed by Surgery Completed NCT00513539 Phase 3 porfimer sodium
23 Fluorouracil, Cisplatin, and Radiation Therapy or Gemcitabine and Oxaliplatin in Treating Patients With Nonmetastatic Biliary Tract Cancer That Cannot Be Removed By Surgery Completed NCT00304135 Phase 2, Phase 3 cisplatin;gemcitabine hydrochloride;oxaliplatin
24 Gemcitabine With or Without Cisplatin in Treating Patients With Unresectable Locally Advanced or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors Completed NCT00262769 Phase 3 cisplatin;gemcitabine hydrochloride
25 Adjuvant Chemotherapy for Biliary Tract Cancer After Curative Resection Recruiting NCT03779035 Phase 3 Gemcitabine;Capecitabine
26 Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers Recruiting NCT03768414 Phase 3 Cisplatin;Gemcitabine Hydrochloride;Nab-paclitaxel
27 Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct Tumours Recruiting NCT02591030 Phase 2, Phase 3 GEMCIS;mFolfirinox
28 Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma Recruiting NCT03086993 Phase 2, Phase 3 Cisplatin and Gemcitabine
29 Perioperative Therapy Preoperative Chemotherapy Versus Chemoradiotherapy in Locally Advanced Gall Bladder Cancers Recruiting NCT02867865 Phase 2, Phase 3 Gemcitabine;Cisplatin
30 Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy Recruiting NCT02853474 Phase 3
31 Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer Recruiting NCT02170090 Phase 3 Gemcitabine;Cisplatin;Capecitabine
32 Photodynamic Therapy (PDT) for Palliation of Cholangiocarcinoma Recruiting NCT01755013 Phase 2, Phase 3
33 Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer Active, not recruiting NCT03093870 Phase 2, Phase 3 Varlitinib;Capecitabine;Placebo (for Varlitinib)
34 GEM/Cisplatin/S-1 vs GEM/Cisplatin for Biliary Tract Cancer Active, not recruiting NCT02182778 Phase 3 Gemcitabine/Cisplatin;Gemcitabine/Cisplatin /S-1
35 Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers Active, not recruiting NCT01926236 Phase 3 L-folinic acid;5 FU;Oxaliplatin
36 Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers Active, not recruiting NCT02349412 Phase 3
37 Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC Not yet recruiting NCT03478488 Phase 3 KN035 plus Gemcitabine & oxaliplatin;Gemcitabine & oxaliplatin
38 A Randomized, Open-Label, Comparative, Parallel-Group, Multicenter Study of SPARC1507 Not yet recruiting NCT02597465 Phase 3 SPARC1507;Reference1507
39 Neoadjuvant Chemotherapy With Gemcitabine Plus Cisplatin Followed by Radical Liver Resection Versus Immediate Radical Liver Resection Alone With or Without Adjuvant Chemotherapy in Incidentally Detected Gallbladder Carcinoma After Simple Cholecystectomy or in Front of Radical Resection of BTC Not yet recruiting NCT03673072 Phase 3 Gemcitabine;Cisplatin;Adjuvant chemotherapy
40 Chemotherapy Before & After Surgery in Patients With Resectable Gallbladder Cancer Not yet recruiting NCT03579758 Phase 3 Capecitabine;Cisplatin;Gemcitabine
41 XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors Terminated NCT00090025 Phase 3 becatecarin;5-Fluorouracil Plus Leucovorin
42 Gemcitabine With or Without Capecitabine in Treating Patients With Locally Advanced, Unresectable, or Metastatic Biliary Cancer Terminated NCT00658593 Phase 3 capecitabine;gemcitabine hydrochloride
43 Escitalopram in Treating Depression in Patients With Advanced Lung or Gastrointestinal Cancer Terminated NCT00387348 Phase 3 escitalopram oxalate;Placebo
44 Comparison Between Two Methods of Bilateral Stenting for Malignant Hilar Obstruction Withdrawn NCT01622803 Phase 3
45 Stent Placement With or Without Photodynamic Therapy Using Porfimer Sodium as Palliative Treatment in Treating Patients With Stage III or Stage IV Cholangiocarcinoma That Cannot Be Removed By Surgery Withdrawn NCT00253617 Phase 3 porfimer sodium
46 Immunotherapy Using Precision T Cells Specific to Personalized Neo-antigen for the Treatment of Advanced Malignant Tumor of Biliary Tract Unknown status NCT02632019 Phase 1, Phase 2 Gemcitabine
47 Effects of OXY111A in Primary and Secondary Hepato-Pancreato-Biliary Neoplasm Unknown status NCT02528526 Phase 1, Phase 2 OXY111A
48 GAMBIT Trial: Cisplatin Plus Irinotecan in the Treatment of Gallbladder or Biliary Tract Cancer Unknown status NCT01859728 Phase 2 Irinotecan;Cisplatin;Cisplatin;Gemcitabine
49 Phase II Study of FOLFOXIRI in Patients With Locally Advanced or Metastatic Biliary Tract Cancer Unknown status NCT01494363 Phase 2 Fluorouracil;Leucovorin;Oxaliplatin;Irinotecan
50 Docetaxel and Oxaliplatin Combination With Locally Advanced or Metastatic Biliary Tract Cancer Unknown status NCT01234051 Phase 2 Docetaxel, Oxaliplatin

Search NIH Clinical Center for Biliary Tract Neoplasm

Genetic Tests for Biliary Tract Neoplasm

Genetic tests related to Biliary Tract Neoplasm:

# Genetic test Affiliating Genes
1 Biliary Tract Neoplasm 29

Anatomical Context for Biliary Tract Neoplasm

MalaCards organs/tissues related to Biliary Tract Neoplasm:

41
Liver, Small Intestine, Lung, Pancreas, Nk Cells, Lymph Node, Bone

The Foundational Model of Anatomy Ontology organs/tissues related to Biliary Tract Neoplasm:

19
The Biliary Tract

Publications for Biliary Tract Neoplasm

Articles related to Biliary Tract Neoplasm:

(show top 50) (show all 276)
# Title Authors Year
1
Albumin-Indocyanine Green Evaluation Grading System Predicts Post-Hepatectomy Liver Failure for Biliary Tract Cancer. ( 29339651 )
2019
2
Utility of convex EUS for preoperative vascular evaluation of malignant biliary tract neoplasm. ( 29468057 )
2018
3
Smoking, alcohol consumption, and risks for biliary tract cancer and intrahepatic bile duct cancer. ( 29760302 )
2018
4
ASO Author Reflections: Hypoxia-Induced PLOD2 Is a Key Regulator in Epithelial-Mesenchymal Transition and Chemoresistance in Biliary Tract Cancer. ( 30167909 )
2018
5
Hypoxia-Induced PLOD2 is a Key Regulator in Epithelial-Mesenchymal Transition and Chemoresistance in Biliary Tract Cancer. ( 30105440 )
2018
6
The maximum chemiluminescence intensity predicts severe neutropenia in gemcitabine-treated patients with pancreatic or biliary tract cancer. ( 30218151 )
2018
7
PI3K-mTOR pathway identified as a potential therapeutic target in biliary tract cancer using a newly established patient-derived cell panel assay. ( 29474549 )
2018
8
The Modified Glasgow Prognostic Score in Patients with Gemcitabine-refractory Biliary Tract Cancer. ( 29491113 )
2018
9
Survival rates are higher in married patients with biliary tract cancer: a population-based study. ( 29507708 )
2018
10
Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study. ( 29527009 )
2018
11
Diagnostic usefulness of KL-6 concentration of bile in biliary tract cancer. ( 29541466 )
2018
12
Tumor-infiltrating mast cells predict prognosis and gemcitabine-based adjuvant chemotherapeutic benefit in biliary tract cancer patients. ( 29562907 )
2018
13
The prognostic impact of differentiation at the invasive front of biliary tract cancer. ( 29572828 )
2018
14
Human epidermal growth factor receptor 2, epidermal growth factor receptor, and c-MET overexpression and survival in biliary tract cancer: A meta-analysis. ( 29578146 )
2018
15
Single-institution experience with gemcitabine-cisplatin combination therapy as a second-line treatment for patients with unresectable biliary tract cancer after failure of gemcitabine-S-1 combination therapy: a prospective feasibility study. ( 29594362 )
2018
16
Body mass index and weight change during initial period of chemotherapy affect survival outcome in advanced biliary tract cancer patients. ( 29608578 )
2018
17
Biliary Tract Cancer: Implicated Immune-Mediated Pathways and Their Associated Potential Targets. ( 29705791 )
2018
18
Feasibility study of postoperative adjuvant chemotherapy with S-1 in patients with biliary tract cancer. ( 29705976 )
2018
19
Prognostic factors for operable biliary tract cancer: serum levels of lactate dehydrogenase, a strong association with survival. ( 29765232 )
2018
20
Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer. ( 29785570 )
2018
21
Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF). ( 29853658 )
2018
22
Early Skin Rash and Cetuximab-Based Therapy of Advanced Biliary Tract Cancer. ( 29858970 )
2018
23
New developments in systemic therapy for advanced biliary tract cancer. ( 29893894 )
2018
24
Peribiliary Glands as the Cellular Origin of Biliary Tract Cancer. ( 29895797 )
2018
25
Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial. ( 29925934 )
2018
26
A nomogram to predict overall survival for biliary tract cancer. ( 29942155 )
2018
27
A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin. ( 29955136 )
2018
28
Generation of sphingosine-1-phosphate is enhanced in biliary tract cancer patients and is associated with lymphatic metastasis. ( 30018456 )
2018
29
The population-based incidence and mortality of biliary tract cancer in Sweden. ( 30025250 )
2018
30
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastases of pancreas and biliary tract cancer. ( 30062506 )
2018
31
PHOTOSTENT-02: porfimer sodium photodynamic therapy plus stenting versus stenting alone in patients with locally advanced or metastatic biliary tract cancer. ( 30094069 )
2018
32
Individualized metabolic profiling stratifies pancreatic and biliary tract cancer: a useful tool for innovative screening programs and predictive strategies in healthcare. ( 30174764 )
2018
33
Biliary Tract Cancer: State of the Art and potential role of DNA Damage Repair. ( 30218788 )
2018
34
Clinical Benefit of Maintenance Therapy for Advanced Biliary Tract Cancer Patients Showing No Progression after First-Line Gemcitabine Plus Cisplatin. ( 30282446 )
2018
35
Jab1 Silencing Inhibits Proliferation and Sensitizes to Cisplatin in Biliary Tract Cancer. ( 30282449 )
2018
36
Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy. ( 30298469 )
2018
37
The impact of skeletal muscle mass on survival outcome in biliary tract cancer patients. ( 30303998 )
2018
38
Second-line chemotherapy in patients with advanced or recurrent biliary tract cancer: a single center, retrospective analysis of 294 cases. ( 30324343 )
2018
39
CT-based Radiomics for Biliary Tract Cancer: A Possible Solution for Predicting Lymph Node Metastases. ( 30325279 )
2018
40
Biliary Tract Cancer at CT: A Radiomics-based Model to Predict Lymph Node Metastasis and Survival Outcomes. ( 30325283 )
2018
41
Klebsiella-related liver abscess as a manifestation of occult colorectal and biliary tract cancer. ( 30325461 )
2018
42
A Prospective, Randomized Phase II Study of Adjuvant Gemcitabine Versus S-1 After Major Hepatectomy for Biliary Tract Cancer (KHBO 1208): Kansai Hepato-Biliary Oncology Group. ( 30339627 )
2018
43
A Case of Metastatic Biliary Tract Cancer Diagnosed Through Identification of an IDH1 Mutation. ( 30352944 )
2018
44
Yttrium-90 glass microspheres radioembolization (RE) for biliary tract cancer: a large single-center experience. ( 30374530 )
2018
45
Evaluation of positive ductal margins of biliary tract cancer in intraoperative histological examination. ( 30405808 )
2018
46
Comparison between autologous and homologous blood transfusions in liver resection for biliary tract cancer: A propensity score matching analysis. ( 30428161 )
2018
47
The efficacy of serum cell death biomarkers for diagnosing biliary tract cancer. ( 30451962 )
2018
48
Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer. ( 30514066 )
2018
49
Human equilibrative nucleoside transporter 1 (hENT1) expression as a predictive biomarker for gemcitabine chemotherapy in biliary tract cancer. ( 30557411 )
2018
50
A Multicenter Phase II Study of Gemcitabine, Capecitabine, and Bevacizumab for Locally Advanced or Metastatic Biliary Tract Cancer. ( 27849649 )
2018

Variations for Biliary Tract Neoplasm

Cosmic variations for Biliary Tract Neoplasm:

9 (show top 50) (show all 1681)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6974042 ZFHX3 biliary tract,bile duct,carcinoma,NS c.6964C>T p.R2322* 16:72795718-72795718 18
2 COSM6957143 ZFHX3 biliary tract,bile duct,carcinoma,NS c.3529+1G>A p.? 16:72829778-72829778 18
3 COSM6928728 YAP1 biliary tract,bile duct,carcinoma,NS c.434C>G p.T145S 11:102114256-102114256 18
4 COSM6986174 XPO1 biliary tract,bile duct,carcinoma,NS c.273G>T p.W91C 2:61522639-61522639 18
5 COSM6975271 XPO1 biliary tract,bile duct,carcinoma,NS c.729G>T p.E243D 2:61498703-61498703 18
6 COSM6985358 XPO1 biliary tract,bile duct,carcinoma,NS c.338C>T p.T113M 2:61502274-61502274 18
7 COSM6923580 TSC1 biliary tract,bile duct,carcinoma,NS c.2551C>T p.Q851* 9:132900789-132900789 18
8 COSM4172016 TSC1 biliary tract,bile duct,carcinoma,NS c.737+1G>A p.? 9:132921362-132921362 18
9 COSM308173 TRIM28 biliary tract,bile duct,carcinoma,NS c.1475G>T p.R492L 19:58549053-58549053 18
10 COSM44463 TP53 biliary tract,bile duct,carcinoma,NS c.848G>T p.R283L 17:7673772-7673772 18
11 COSM43687 TP53 biliary tract,bile duct,carcinoma,NS c.641A>G p.H214R 17:7674890-7674890 18
12 COSM10687 TP53 biliary tract,bile duct,carcinoma,NS c.527G>A p.C176Y 17:7675085-7675085 18
13 COSM10731 TP53 biliary tract,bile duct,carcinoma,NS c.707A>G p.Y236C 17:7674256-7674256 18
14 COSM10662 TP53 biliary tract,bile duct,carcinoma,NS c.743G>A p.R248Q 17:7674220-7674220 18
15 COSM11073 TP53 biliary tract,bile duct,carcinoma,NS c.1024C>T p.R342* 17:7670685-7670685 18
16 COSM43751 TP53 biliary tract,bile duct,carcinoma,NS c.673-1G>A p.? 17:7674291-7674291 18
17 COSM44918 TP53 biliary tract,bile duct,carcinoma,NS c.844C>A p.R282R 17:7673776-7673776 18
18 COSM44240 TP53 biliary tract,bile duct,carcinoma,NS c.514G>T p.V172F 17:7675098-7675098 18
19 COSM10704 TP53 biliary tract,bile duct,carcinoma,NS c.844C>T p.R282W 17:7673776-7673776 18
20 COSM22908 TP53 biliary tract,bile duct,carcinoma,NS c.376-1G>T p.? 17:7675237-7675237 18
21 COSM44143 TP53 biliary tract,bile duct,carcinoma,NS c.919+1G>A p.? 17:7673700-7673700 18
22 COSM43836 TP53 biliary tract,bile duct,carcinoma,NS c.475G>C p.A159P 17:7675137-7675137 18
23 COSM10742 TP53 biliary tract,bile duct,carcinoma,NS c.578A>G p.H193R 17:7674953-7674953 18
24 COSM1522202 TP53 biliary tract,bile duct,carcinoma,NS c.1051A>T p.K351* 17:7670658-7670658 18
25 COSM10727 TP53 biliary tract,bile duct,carcinoma,NS c.438G>A p.W146* 17:7675174-7675174 18
26 COSM44786 TP53 biliary tract,bile duct,carcinoma,NS c.694A>C p.I232L 17:7674269-7674269 18
27 COSM10648 TP53 biliary tract,bile duct,carcinoma,NS c.524G>A p.R175H 17:7675088-7675088 18
28 COSM10660 TP53 biliary tract,bile duct,carcinoma,NS c.818G>A p.R273H 17:7673802-7673802 18
29 COSM43596 TP53 biliary tract,bile duct,carcinoma,NS c.841G>A p.D281N 17:7673779-7673779 18
30 COSM43909 TP53 biliary tract,bile duct,carcinoma,NS c.817C>A p.R273S 17:7673803-7673803 18
31 COSM11090 TP53 biliary tract,bile duct,carcinoma,NS c.541C>T p.R181C 17:7675071-7675071 18
32 COSM6917440 TP53 biliary tract,bile duct,carcinoma,NS c.736A>C p.M246L 17:7674227-7674227 18
33 COSM6081949 TP53 biliary tract,bile duct,carcinoma,NS c.1060C>T p.Q354* 17:7670649-7670649 18
34 COSM10690 TP53 biliary tract,bile duct,carcinoma,NS c.473G>A p.R158H 17:7675139-7675139 18
35 COSM10656 TP53 biliary tract,bile duct,carcinoma,NS c.742C>T p.R248W 17:7674221-7674221 18
36 COSM10645 TP53 biliary tract,bile duct,carcinoma,NS c.527G>T p.C176F 17:7675085-7675085 18
37 COSM11071 TP53 biliary tract,bile duct,carcinoma,NS c.1009C>T p.R337C 17:7670700-7670700 18
38 COSM10749 TP53 biliary tract,bile duct,carcinoma,NS c.830G>T p.C277F 17:7673790-7673790 18
39 COSM44151 TP53 biliary tract,bile duct,carcinoma,NS c.535C>A p.H179N 17:7675077-7675077 18
40 COSM44262 TP53 biliary tract,bile duct,carcinoma,NS c.808T>C p.F270L 17:7673812-7673812 18
41 COSM11078 TP53 biliary tract,bile duct,carcinoma,NS c.1027G>T p.E343* 17:7670682-7670682 18
42 COSM10659 TP53 biliary tract,bile duct,carcinoma,NS c.817C>T p.R273C 17:7673803-7673803 18
43 COSM43947 TP53 biliary tract,bile duct,carcinoma,NS c.614A>G p.Y205C 17:7674917-7674917 18
44 COSM10883 TP53 biliary tract,bile duct,carcinoma,NS c.731G>A p.G244D 17:7674232-7674232 18
45 COSM44523 TP53 biliary tract,bile duct,carcinoma,NS c.863A>G p.N288S 17:7673757-7673757 18
46 COSM10672 TP53 biliary tract,bile duct,carcinoma,NS c.577C>T p.H193Y 17:7674954-7674954 18
47 COSM11355 TP53 biliary tract,bile duct,carcinoma,NS c.737T>C p.M246T 17:7674226-7674226 18
48 COSM44226 TP53 biliary tract,bile duct,carcinoma,NS c.380C>T p.S127F 17:7675232-7675232 18
49 COSM10725 TP53 biliary tract,bile duct,carcinoma,NS c.701A>G p.Y234C 17:7674262-7674262 18
50 COSM43850 TP53 biliary tract,bile duct,carcinoma,NS c.659A>C p.Y220S 17:7674872-7674872 18

Expression for Biliary Tract Neoplasm

Search GEO for disease gene expression data for Biliary Tract Neoplasm.

Pathways for Biliary Tract Neoplasm

Pathways related to Biliary Tract Neoplasm according to GeneCards Suite gene sharing:

(show top 50) (show all 54)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.58 CDKN2A CDX2 MUC1 MUC2 MUC4 SMAD4
2
Show member pathways
12.85 CDKN2A HRAS KRAS SMAD4 TP53
3
Show member pathways
12.67 CDKN2A HRAS KRAS TP53
4
Show member pathways
12.67 CDKN2A HRAS KRAS SMAD4 TP53
5 12.63 CDKN2A HRAS KRAS SMAD4 TP53
6
Show member pathways
12.62 CDKN2A HRAS KRAS TP53
7 12.33 CDKN2A HRAS KRAS TP53
8
Show member pathways
12.32 HRAS KRAS MUC1 SMAD4 TP53
9 12.19 HRAS KRAS TP53
10
Show member pathways
12.15 HRAS KRAS TP53
11
Show member pathways
12.14 MUC1 MUC2 MUC4
12
Show member pathways
12.13 HRAS KRAS MUC1 MUC2 MUC4
13 12.1 CDKN2A HRAS KRAS TP53
14 12.07 KRAS SMAD4 TP53
15 12.06 CDKN2A HRAS KRAS SMAD4 TP53
16
Show member pathways
12.05 HRAS KRAS TP53
17 12.03 HRAS KRAS TP53
18 12.03 KRAS SMAD4 TP53
19
Show member pathways
12.02 HRAS KRAS TP53
20
Show member pathways
12.01 HRAS KRAS TP53
21
Show member pathways
11.99 MUC1 MUC2 MUC4
22 11.98 CDKN2A HRAS KRAS TP53
23 11.96 HRAS KRAS SMAD4
24 11.95 CDKN2A SMAD4 TP53
25
Show member pathways
11.95 HRAS KRAS SMAD4
26 11.94 HRAS KRAS SMAD4
27
Show member pathways
11.92 HRAS KRAS TP53
28 11.92 HRAS KRAS TP53
29 11.85 HRAS KRAS TP53
30 11.84 HRAS KRAS TP53
31
Show member pathways
11.83 CDKN2A CDX2 HRAS KRAS MUC2 SMAD4
32
Show member pathways
11.8 MUC1 MUC2 MUC4
33 11.76 HRAS KRAS SMAD4
34 11.75 CDKN2A HRAS KRAS TP53
35 11.69 CDKN2A HRAS SMAD4 TP53
36 11.6 CDKN2A SMAD4 TP53
37 11.54 HRAS KRAS TP53
38 11.53 HRAS KRAS TP53
39 11.48 HRAS KRAS TP53
40 11.41 CDKN2A HRAS KRAS SMAD4 TP53
41 11.32 CDKN2A HRAS KRAS TP53
42 11.22 CDKN2A TP53
43 11.19 HRAS KRAS
44
Show member pathways
11.17 HRAS KRAS
45 11.17 HRAS KRAS TP53
46
Show member pathways
11.12 HRAS KRAS
47 11.11 HRAS KRAS SMAD4
48 11.06 HRAS KRAS
49 11.03 HRAS KRAS
50 11.03 CDKN2A TP53

GO Terms for Biliary Tract Neoplasm

Cellular components related to Biliary Tract Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Golgi lumen GO:0005796 8.8 MUC1 MUC2 MUC4

Biological processes related to Biliary Tract Neoplasm according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.88 CDKN2A CDX2 SMAD4 TP53
2 negative regulation of cell proliferation GO:0008285 9.78 CDKN2A HRAS SMAD4 TP53
3 positive regulation of gene expression GO:0010628 9.76 CDKN2A HRAS KRAS TP53
4 cell cycle arrest GO:0007050 9.67 CDKN2A HRAS TP53
5 negative regulation of cell growth GO:0030308 9.58 CDKN2A SMAD4 TP53
6 intrinsic apoptotic signaling pathway GO:0097193 9.57 HRAS TP53
7 cell aging GO:0007569 9.56 HRAS TP53
8 cellular response to gamma radiation GO:0071480 9.55 HRAS TP53
9 cellular senescence GO:0090398 9.54 CDKN2A HRAS
10 regulation of long-term neuronal synaptic plasticity GO:0048169 9.52 HRAS KRAS
11 positive regulation of cellular senescence GO:2000774 9.51 CDKN2A KRAS
12 maintenance of gastrointestinal epithelium GO:0030277 9.43 MUC2 MUC4
13 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.37 MUC1 TP53
14 O-glycan processing GO:0016266 9.33 MUC1 MUC2 MUC4
15 replicative senescence GO:0090399 9.32 CDKN2A TP53
16 response to isolation stress GO:0035900 9.26 HRAS KRAS
17 Ras protein signal transduction GO:0007265 9.26 CDKN2A HRAS KRAS TP53
18 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.02 HRAS KRAS MUC1 MUC2 MUC4

Sources for Biliary Tract Neoplasm

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....